AZD8309

• CAT Number: I022887
• CAS Number: 333742-48-6
• Molecular Formula: C15H14F2N4O2S2
• Molecular Weight: 384.42
• Purity: ≥95%
• Synonyms: 5-[(2,3-difluorophenyl)methylsulfanyl]-7-[[(2R)-1-hydroxypropan-2-yl]amino]-3H-[1,3]thiazolo[4,5-d]pyrimidin-2-one
• InChI: InChI=1S/C15H14F2N4O2S2/c1-7(5-22)18-12-11-13(21-15(23)25-11)20-14(19-12)24-6-8-3-2-4-9(16)10(8)17/h2-4,7,22H,5-6H2,1H3,(H2,18,19,20,21,23)/t7-/m1/s1
• InChIKey: SRHSMXLXWORYJK-SSDOTTSWSA-N
• SMILES: C[C@H](CO)NC1=NC(=NC2=C1SC(=O)N2)SCC3=C(C(=CC=C3)F)F

AZD8309（Cat No.:I022887）is a small molecule inhibitor developed by AstraZeneca, designed to target specific enzymes or receptors involved in cellular processes related to disease progression, particularly in cancer. It is known for its potential to modulate the immune system or regulate tumor microenvironments to enhance anti-cancer responses. AZD8309 is part of ongoing research into targeted therapies, aiming to improve treatment outcomes for cancers that are resistant to traditional therapies. Clinical trials are being conducted to assess its safety, efficacy, and the appropriate patient populations for its use in oncology treatments.